CD34 and Epstein-Barr virus infection: The present study showed that there was no significant difference in CMV and EBV infection rates between the two groups, which might be attributed to the active prophylactic use of antiviral drugs before and after transplantation, and sufficient MNC and CD34+ cells to facilitate the engraftment.